Acute encephalopathy with combination dabrafenib/trametinib therapy

被引：6

作者：

Cooper, Jalyn ^{[1
]}

Kodali, Dheeraj ^{[2
]}

Higa, Gerald M. ^{[1
,2
]}

机构：

[1] West Virginia Univ, Sch Pharm, Dept Clin Pharm, Morgantown, WV 26506 USA

[2] West Virginia Univ, Dept Clin Pharm, Sch Med, Sect Hematol Oncol, Morgantown, WV USA

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2017年 / 23卷 / 04期

关键词：

Acute encephalopathy; BRAF V600 mutation; dabrafenib; melanoma; METASTATIC MELANOMA; MEK INHIBITION; COMBINED BRAF; DABRAFENIB;

D O I：

10.1177/1078155216638551

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug.

引用

页码：313 / 317

页数：5

共 14 条

[1]

[Anonymous], AM J EMERG MED

[2] Cognitive Profile of Disorders Associated With Dysregulation of the RAS/MAPK Signaling Cascade [J].

Cesarini, Laura ;

Alfieri, Paolo ;

Pantaleoni, Francesca ;

Vasta, Isabella ;

Cerutti, Marta ;

Petrangeli, Valentina ;

Mariotti, Paolo ;

Leoni, Chiara ;

Ricci, Daniela ;

Vicari, Stefano ;

Selicorni, Angelo ;

Tartaglia, Marco ;

Mercuri, Eugenio ;

Zampino, Giuseppe .

AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2009, 149A (02) :140-146

[3] Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial [J].

Falchook, Gerald S. ;

Long, Georgina V. ;

Kurzrock, Razelle ;

Kim, Kevin B. ;

Arkenau, Tobias H. ;

Brown, Michael P. ;

Hamid, Omid ;

Infante, Jeffrey R. ;

Millward, Michael ;

Pavlick, Anna C. ;

O'Day, Steven J. ;

Blackman, Samuel C. ;

Curtis, C. Martin ;

Lebowitz, Peter ;

Ma, Bo ;

Ouellet, Daniele ;

Kefford, Richard F. .

LANCET, 2012, 379 (9829) :1893-1901

[4] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [J].

Flaherty, Keith T. ;

Robert, Caroline ;

Hersey, Peter ;

Nathan, Paul ;

Garbe, Claus ;

Milhem, Mohammed ;

Demidov, Lev V. ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

Mohr, Peter ;

Dummer, Reinhard ;

Trefzer, Uwe ;

Larkin, James M. G. ;

Utikal, Jochen ;

Dreno, Brigitte ;

Nyakas, Marta ;

Middleton, Mark R. ;

Becker, Juergen C. ;

Casey, Michelle ;

Sherman, Laurie J. ;

Wu, Frank S. ;

Ouellet, Daniele ;

Martin, Anne-Marie ;

Patel, Kiran ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) :107-114

[5] Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial [J].

Hauschild, Axel ;

Grob, Jean-Jacques ;

Demidov, Lev V. ;

Jouary, Thomas ;

Gutzmer, Ralf ;

Millward, Michael ;

Rutkowski, Piotr ;

Blank, Christian U. ;

Miller, Wilson H., Jr. ;

Kaempgen, Eckhart ;

Martin-Algarra, Salvador ;

Karaszewska, Boguslawa ;

Mauch, Cornelia ;

Chiarion-Sileni, Vanna ;

Martin, Anne-Marie ;

Swann, Suzanne ;

Haney, Patricia ;

Mirakhur, Beloo ;

Guckert, Mary E. ;

Goodman, Vicki ;

Chapman, Paul B. .

LANCET, 2012, 380 (9839) :358-365

[6] Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial [J].

Infante, Jeffrey R. ;

Fecher, Leslie A. ;

Falchook, Gerald S. ;

Nallapareddy, Sujatha ;

Gordon, Michael S. ;

Becerra, Carlos ;

DeMarini, Douglas J. ;

Cox, Donna S. ;

Xu, Yanmei ;

Morris, Shannon R. ;

Peddareddigari, Vijay G. R. ;

Le, Ngocdiep T. ;

Hart, Lowell ;

Bendell, Johanna C. ;

Eckhardt, Gail ;

Kurzrock, Razelle ;

Flaherty, Keith ;

Burris, Howard A., III ;

Messersmith, Wells A. .

LANCET ONCOLOGY, 2012, 13 (08) :773-781

[7]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]

[8] Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects! [J].

Khurana, Arushi ;

Dasanu, Constantin A. .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (06) :443-450

[9] A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma [J].

Kirkwood, JM ;

Manola, J ;

Ibrahim, J ;

Sondak, V ;

Ernstoff, MS ;

Rao, U .

CLINICAL CANCER RESEARCH, 2004, 10 (05) :1670-1677

[10] Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [J].

Long, G. V. ;

Stroyakovskiy, D. ;

Gogas, H. ;

Levchenko, E. ;

de Braud, F. ;

Larkin, J. ;

Garbe, C. ;

Jouary, T. ;

Hauschild, A. ;

Grob, J. J. ;

Sileni, V. Chiarion ;

Lebbe, C. ;

Mandala, M. ;

Millward, M. ;

Arance, A. ;

Bondarenko, I. ;

Haanen, J. B. A. G. ;

Hansson, J. ;

Utikal, J. ;

Ferraresi, V. ;

Kovalenko, N. ;

Mohr, P. ;

Probachai, V. ;

Schadendorf, D. ;

Nathan, P. ;

Robert, C. ;

Ribas, A. ;

DeMarini, D. J. ;

Irani, J. G. ;

Casey, M. ;

Ouellet, D. ;

Martin, A. -M. ;

Le, N. ;

Patel, K. ;

Flaherty, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1877-1888

← 1 2 →